NOVN Stock Overview
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF93.37 |
| 52 Week High | CHF94.77 |
| 52 Week Low | CHF83.00 |
| Beta | 0.47 |
| 1 Month Change | 9.17% |
| 3 Month Change | 4.25% |
| 1 Year Change | 3.16% |
| 3 Year Change | 17.74% |
| 5 Year Change | 7.01% |
| Change since IPO | 150.99% |
Recent News & Updates
Shareholder Returns
| NOVN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 1.1% | 3.1% | 2.0% |
| 1Y | 3.2% | 11.1% | 1.0% |
Return vs Industry: NOVN underperformed the Swiss Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: NOVN exceeded the Swiss Market which returned 1% over the past year.
Price Volatility
| NOVN volatility | |
|---|---|
| NOVN Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 3.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.1% |
| 10% least volatile stocks in CH Market | 1.8% |
Stable Share Price: NOVN has not had significant price volatility in the past 3 months.
Volatility Over Time: NOVN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG Fundamentals Summary
| NOVN fundamental statistics | |
|---|---|
| Market cap | CHF190.51b |
| Earnings (TTM) | CHF8.27b |
| Revenue (TTM) | CHF43.35b |
23.0x
P/E Ratio4.4x
P/S RatioIs NOVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVN income statement (TTM) | |
|---|---|
| Revenue | US$47.73b |
| Cost of Revenue | US$12.12b |
| Gross Profit | US$35.61b |
| Other Expenses | US$26.51b |
| Earnings | US$9.11b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | 4.46 |
| Gross Margin | 74.61% |
| Net Profit Margin | 19.08% |
| Debt/Equity Ratio | 64.2% |
How did NOVN perform over the long term?
See historical performance and comparison